Therapeutic Potential of Mesenchymal Stem Cell–Derived Secretome in Bacterial Infections: Bridging Acute Inflammation and Biofilm‐Associated Diseases
International Journal of Microbiology · 2026-01 · 2026 (1)
DOI: 10.1155/ijm/4040189 ↗Abstract
Incomplete bacterial eradication despite appropriate antimicrobial therapy contributes to the progression of some bacterial infections toward chronic or recurrent disease. Beyond genetically encoded antimicrobial resistance, bacterial persistence may be sustained by phenotypically tolerant subpopulations, including persister cells, together with biofilm‐associated growth. These states arise within heterogeneous microenvironments shaped by antimicrobial exposure, immune pressure, nutrient and oxygen limitation, and tissue injury. Failure of inflammation to resolve effectively may further promote persistent inflammatory signaling, impaired phagocytic function, localized hypoxia, and extracellular matrix disruption, thereby creating conditions that favor bacterial survival and biofilm stability. This review critically examines the mesenchymal stem cell–derived secretome as a potential host‐directed adjunct for persistent and biofilm‐associated bacterial infections. Rather than reiterating its antimicrobial, immunomodulatory, and regenerative properties, we integrate direct antibiofilm and antimicrobial evidence with indirect host‐mediated mechanisms involving NF‐ κ B modulation, proresolving macrophage responses, efferocytosis, and tissue repair. These actions may converge on host–pathogen niches that sustain bacterial persistence. However, direct evidence that MSC‐secretome reduces persister frequency, reverses bacterial dormancy, or eliminates persister populations remains limited. By distinguishing experimentally demonstrated effects from mechanistically inferred actions, this review proposes a host–pathogen ecological framework for evaluating MSC‐secretome in bacterial persistence. Current evidence remains predominantly preclinical. Key priorities include improved product standardization and potency assessment, validation in physiologically relevant chronic infection models, and clearer definition of dosing, delivery, and combination strategies with conventional antimicrobials.
EUVIMED